Lingchuang Yigu Announces Completion of ￥10 Million Pre-A Funding Round

(VCBeat) July. 12, 2021 -- Recently, Beijing Lingchuang Yigu Technology Development Co., Ltd. ("Lingchuang Yigu") announced that it has secured of tens of millions of yuan in Series Pre-A round, led by China Growth Capital, with participation from Med-Fine Capital and Huagai Capital, and the angel round lead investor Cowin Capital. The completion of this round will accelerate the pace of Lingchuang Yigu in the fields of R&D team building, product patent application, product registration and so on.

Lingchuang Yigu was founded in June 2016, with academician Han Jisheng, the founder of the field of neuroregulation in China, and Professor Fan Bifa, the academic leader of pain medicine in China as the chief scientists. Taking the innovative wireless implantable neural electrical stimulation technology platform as the breakthrough point, Lingchuang Yigu is committed to providing innovative solutions of implantable neural electrical stimulation treatment for patients with nerve functional diseases. The company's first product to market will be China's first and only wireless implantable spinal cord electrical stimulation product independently developed for chronic pain.

Mr. Xu Tianrui, founder and CEO of Lingchuang Yigu, said that the application prospect of neural regulation technology is very broad. Spinal cord stimulation (SCS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS) are widely used in chronic pain, primary Parkinson's disease, major depression, Alzheimer's disease, refractory epilepsy, arthritis, urination dysfunction, inflammatory bowel disease and other fields. At present, implantable nerve regulation devices have been clinically proven to be one of the most effective treatments in this field.

CGC is a China-focused seed and early venture investor since 2006. We back extraordinary entrepreneurs from seed to early growth in enterprise, frontier tech, life science, marketplace and consumer verticals.They pioneered fintech and enterprise innovations in China since founding in 2006 with a unique portfolio of fintech, enterprise software, frontier technology and marketplace players.

Founded in 2014 at China's financial hub-Shanghai, Med-Fine Capital is an investment fund. Currently, it manages11 investment funds, of which the amount value has reached nearly 800 million yuan.

Med-Fine Capital mainly invests in the healthcare and bioscience industry. The financial services include equity investments (VC/PE), PIPE, FOF (Fund of Funds), securities investing, M&A and etc.